Experiments were performed on uteri from @entity172 -primed female @entity35 . @entity1812 (BK) (10(-8) M) significantly augmented biosynthesis of @entity3774 (PGF2alpha) and @entity1421 ( @entity1421 ), and this synthesis was completely blocked by @entity7293 ( @entity20759 ) (300 microM), a competitive inhibitor of @entity842 synthase (NOS). Blockade of @entity3009 synthesis by @entity3352 caused rapid dissipation of @entity245 ( @entity245 ) induced by BK. Blockade of NOS with @entity20759 had similar but less marked effects. Combining the two inhibitors produced an even more rapid decay in @entity245 , suggesting that BK-induced NO release maintains @entity245 by release of prostanoids. The decline of frequency of contraction (FC) was not significantly altered by either @entity3352 or @entity20759 but was markedly accelerated by combination of the inhibitors, which suggests that PGs maintain FC and therefore FC decline is accelerated only when PG production is blocked completely by combination of the two inhibitors of PG synthesis. The increase in @entity245 induced by @entity398 was unaltered by @entity3352 , @entity20759 or their combination indicating that neither NO nor PGs are involved in the contractions induced by @entity398 . However, the decline in FC with time was significantly reduced by the inhibitor of NOS, @entity20759 , suggesting that FC decay following @entity398 is caused by NO released by the contractile process. In the case of PGF2alpha, @entity20759 resulted in increased initial @entity245 and FC. The decline in FC was rapid and dramatically inhibited by @entity20759 . Receptor-mediated contraction by BK, @entity398 , and PGF2alpha is modulated by NO that maintains @entity245 by releasing PGs but reduces @entity245 and FC via @entity8262 .

@entity842 in the contractile action of XXXX , @entity398 , and @entity3774 in the estrogenized @entity35 uterus.

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity398 :: ('MESH:D010121', 'Chemical') :: ['oxytocin'] @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2'] @entity20759 :: ('MESH:C061666', 'Chemical') :: ['NMMA'] @entity245 :: ('MESH:D002658', 'Disease') :: ['IDT', 'isometric developed tension'] @entity3009 :: ('CHEBI:26333', 'Chemical') :: ['prostaglandin'] @entity7293 :: ('CHEBI:28229', 'Chemical') :: ['NG-monomethyl L-arginine'] @entity8262 :: ('MESH:D006152', 'Chemical') :: ['cyclic GMP'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity3774 :: ('MESH:D015237', 'Chemical') :: ['prostaglandin F2 alpha'] @entity1812 :: ('MESH:D001920', 'Chemical') :: ['Bradykinin'] @entity35 :: ('10116', 'Species') :: ['rats'] @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']
@entity1812 :: (MESH:D001920,Chemical) :: ['bradykinin']
